<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01150097</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001H2304E1</org_study_id>
    <secondary_id>2009-017311-15</secondary_id>
    <nct_id>NCT01150097</nct_id>
  </id_info>
  <brief_title>Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients</brief_title>
  <official_title>Extension Study to the Multicenter, Open-label, Randomized, Controlled Study CRAD001H2304 to Evaluate the Long-term Efficacy and Safety of Concentration-controlled Everolimus in Liver Transplant Recipient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this extension is to evaluate the long-term safety and efficacy of two
      concentration-controlled everolimus regimen in de novo liver transplant recipients. The most
      important long-term safety assessments include evaluation of renal function, progression of
      HCV related allograft fibrosis, and other treatment related effects at Month 36
      post-transplantation compared to extension baseline (Months 24 post-transplantation).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death</measure>
    <time_frame>from months 24 to 36</time_frame>
    <description>The number of participants who experienced composite efficacy failure was analyzed. Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death</measure>
    <time_frame>from months 36 to 48</time_frame>
    <description>The number of participants who experienced composite efficacy failure was analyzed. Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death</measure>
    <time_frame>from months 24 to 36</time_frame>
    <description>The number of participants who experienced graft loss or death was analyzed. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death</measure>
    <time_frame>from months 36 - 48</time_frame>
    <description>The number of participants who experienced graft loss or death was analyzed. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Renal Function</measure>
    <time_frame>from months 24 to 36</time_frame>
    <description>Change in renal function was assessed by the estimated Glomerular Filtration Rate (eGFR) using the abbreviated (4 variables) Modification of Diet in Renal Disease (MDRD-4) formula which was developed by the MDRD Study Group and has been validated in patients with chronic kidney disease. The MDRD-4 formula used for the eGFR calculation is: eGFR (mL/min/1.73m^2) = 186.3*(C^-1.154)*(A^-0.203)*G*R, where C is the serum concentration of creatinine (mg/dL), A is age (years), G=0.742 when gender is female, otherwise G=1, R=1.21 when race is black, otherwise R=1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of tBPAR</measure>
    <time_frame>from months 24 - 36</time_frame>
    <description>The number of participants who had a tBPAR was analyzed. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">284</enrollment>
  <condition>Liver Transplant Recipient</condition>
  <arm_group>
    <arm_group_label>Everolimus + reduced tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus elimination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants were maintained on a whole blood trough level of 6 - 10 ng/mL tacrolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus (reduced tacrolimus)</intervention_name>
    <description>After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.</description>
    <arm_group_label>Everolimus + reduced tacrolimus</arm_group_label>
    <other_name>FK-506,</other_name>
    <other_name>fujimycin,</other_name>
    <other_name>Prograf,</other_name>
    <other_name>Advagraf,</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus (reduced tacrolimus)</intervention_name>
    <description>Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.</description>
    <arm_group_label>Everolimus + reduced tacrolimus</arm_group_label>
    <other_name>RAD001,</other_name>
    <other_name>Zortress,</other_name>
    <other_name>Certican,</other_name>
    <other_name>Afinitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus (tacrolimus elimination)</intervention_name>
    <description>After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.</description>
    <arm_group_label>Tacrolimus elimination</arm_group_label>
    <other_name>FK-506,</other_name>
    <other_name>fujimycin,</other_name>
    <other_name>Prograf,</other_name>
    <other_name>Advagraf,</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus (tacrolimus elimination)</intervention_name>
    <description>Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.</description>
    <arm_group_label>Tacrolimus elimination</arm_group_label>
    <other_name>RAD001,</other_name>
    <other_name>Zortress,</other_name>
    <other_name>Certican,</other_name>
    <other_name>Afinitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus (tacrolimus control)</intervention_name>
    <description>Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.</description>
    <arm_group_label>Tacrolimus control</arm_group_label>
    <other_name>FK-506,</other_name>
    <other_name>fujimycin,</other_name>
    <other_name>Prograf,</other_name>
    <other_name>Advagraf,</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids</intervention_name>
    <description>For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.</description>
    <arm_group_label>Everolimus + reduced tacrolimus</arm_group_label>
    <arm_group_label>Tacrolimus elimination</arm_group_label>
    <arm_group_label>Tacrolimus control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Ability and willingness to adhere to study regimen

          -  Completed core study with assigned regimen;

        Exclusion Criteria:

        Patients fulfilling any of the following criteria are not eligible for inclusion in this
        study:

          -  Severe hypercholesterolemia or hypertriglyceridemia.

          -  Low platelet count.

          -  Low white blood cell count.

          -  Positive test for human immunodeficiency virus (HIV).

          -  Systemic infection requiring active use of IV antibiotics.

          -  Patients in a critical care setting.

          -  Use of prohibited medication.

          -  Use of immunosuppressive agents not utilized in the protocol.

          -  Hypersensitivity to any of the study drugs or similar drugs.

          -  Pregnant or nursing (lactating) women

          -  Women of child-bearing potential not using a highly effective method of birth control.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0293</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-2689</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1118AAT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Martin</city>
        <state>Buenos Aires</state>
        <zip>C1107BEA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21041-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin 4</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>129010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baracaldo</city>
        <state>Pais Vasco</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Hungary</country>
  </removed_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>June 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2010</study_first_posted>
  <results_first_submitted>May 1, 2014</results_first_submitted>
  <results_first_submitted_qc>May 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 30, 2014</results_first_posted>
  <last_update_submitted>March 12, 2015</last_update_submitted>
  <last_update_submitted_qc>March 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver transplantation</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Calcineurin inhibitors</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Renal function</keyword>
  <keyword>Progression of HCV related allograft fibrosis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Two hundred eight four participants were eligible and enrolled into the extension. However, 2 participants withdrew from the extension prior to receiving treatment. Therefore, a total of 282 participants were accounted for in the extension.</recruitment_details>
      <pre_assignment_details>Participants in the tacrolimus control group were studied for 12 months (from months 24 to 36 post transplant). Participants in the tacrolimus elimination and everolimus + reduced tacrolimus groups were studied for a minimum of 12 months up to 24 months (from months 24 to 48 months post transplant) depending on the participant's study start.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Everolimus + Reduced Tacrolimus</title>
          <description>Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.</description>
        </group>
        <group group_id="P2">
          <title>Tacrolimus Elimination</title>
          <description>Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.</description>
        </group>
        <group group_id="P3">
          <title>Tacrolimus Control</title>
          <description>Participants were maintained on a whole blood trough level of 6 - 10 ng/mL tacrolimus.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Months 24 to 36 Post-transplantation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Months 24 to 48 Post-transplantation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Everolimus + Reduced Tacrolimus</title>
          <description>Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.</description>
        </group>
        <group group_id="B2">
          <title>Tacrolimus Elimination</title>
          <description>Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.</description>
        </group>
        <group group_id="B3">
          <title>Tacrolimus Control</title>
          <description>Participants were maintained on a whole blood trough level of 6 - 10 ng/mL tacrolimus.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="106"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="125"/>
            <count group_id="B4" value="282"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="9.57"/>
                    <measurement group_id="B2" value="54.9" spread="10.07"/>
                    <measurement group_id="B3" value="55.2" spread="8.10"/>
                    <measurement group_id="B4" value="54.5" spread="9.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death</title>
        <description>The number of participants who experienced composite efficacy failure was analyzed. Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.</description>
        <time_frame>from months 24 to 36</time_frame>
        <population>All extension participants</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Reduced Tacrolimus</title>
            <description>Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus Elimination</title>
            <description>Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.</description>
          </group>
          <group group_id="O3">
            <title>Tacrolimus Control</title>
            <description>Participants were maintained on a whole blood trough level of 6 - 10 ng/mL tacrolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death</title>
          <description>The number of participants who experienced composite efficacy failure was analyzed. Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.</description>
          <population>All extension participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death</title>
        <description>The number of participants who experienced composite efficacy failure was analyzed. Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.</description>
        <time_frame>from months 36 to 48</time_frame>
        <population>Participants from the everolimus + reduced tacrolimus group and the tacrolimus elimination group</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Reduced Tacrolimus</title>
            <description>Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus Elimination</title>
            <description>Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death</title>
          <description>The number of participants who experienced composite efficacy failure was analyzed. Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.</description>
          <population>Participants from the everolimus + reduced tacrolimus group and the tacrolimus elimination group</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death</title>
        <description>The number of participants who experienced graft loss or death was analyzed. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.</description>
        <time_frame>from months 24 to 36</time_frame>
        <population>All extension participants</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Reduced Tacrolimus</title>
            <description>Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus Elimination</title>
            <description>Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.</description>
          </group>
          <group group_id="O3">
            <title>Tacrolimus Control</title>
            <description>Participants were maintained on a whole blood trough level of 6 - 10 ng/mL tacrolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death</title>
          <description>The number of participants who experienced graft loss or death was analyzed. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.</description>
          <population>All extension participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death</title>
        <description>The number of participants who experienced graft loss or death was analyzed. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.</description>
        <time_frame>from months 36 - 48</time_frame>
        <population>Participants from the everolimus + reduced tacrolimus group and the tacrolimus elimination group</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Reduced Tacrolimus</title>
            <description>Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus Elimination</title>
            <description>Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death</title>
          <description>The number of participants who experienced graft loss or death was analyzed. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.</description>
          <population>Participants from the everolimus + reduced tacrolimus group and the tacrolimus elimination group</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of tBPAR</title>
        <description>The number of participants who had a tBPAR was analyzed. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection.</description>
        <time_frame>from months 24 - 36</time_frame>
        <population>All extension participants</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Reduced Tacrolimus</title>
            <description>Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus Elimination</title>
            <description>Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.</description>
          </group>
          <group group_id="O3">
            <title>Tacrolimus Control</title>
            <description>Participants were maintained on a whole blood trough level of 6 - 10 ng/mL tacrolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of tBPAR</title>
          <description>The number of participants who had a tBPAR was analyzed. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection.</description>
          <population>All extension participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Renal Function</title>
        <description>Change in renal function was assessed by the estimated Glomerular Filtration Rate (eGFR) using the abbreviated (4 variables) Modification of Diet in Renal Disease (MDRD-4) formula which was developed by the MDRD Study Group and has been validated in patients with chronic kidney disease. The MDRD-4 formula used for the eGFR calculation is: eGFR (mL/min/1.73m^2) = 186.3*(C^-1.154)*(A^-0.203)*G*R, where C is the serum concentration of creatinine (mg/dL), A is age (years), G=0.742 when gender is female, otherwise G=1, R=1.21 when race is black, otherwise R=1.</description>
        <time_frame>from months 24 to 36</time_frame>
        <population>The analysis population included extension participants who had both post-extension baseline and month 36 values only.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Reduced Tacrolimus</title>
            <description>Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus Elimination</title>
            <description>Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.</description>
          </group>
          <group group_id="O3">
            <title>Tacrolimus Control</title>
            <description>Participants were maintained on a whole blood trough level of 6 - 10 ng/mL tacrolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Renal Function</title>
          <description>Change in renal function was assessed by the estimated Glomerular Filtration Rate (eGFR) using the abbreviated (4 variables) Modification of Diet in Renal Disease (MDRD-4) formula which was developed by the MDRD Study Group and has been validated in patients with chronic kidney disease. The MDRD-4 formula used for the eGFR calculation is: eGFR (mL/min/1.73m^2) = 186.3*(C^-1.154)*(A^-0.203)*G*R, where C is the serum concentration of creatinine (mg/dL), A is age (years), G=0.742 when gender is female, otherwise G=1, R=1.21 when race is black, otherwise R=1.</description>
          <population>The analysis population included extension participants who had both post-extension baseline and month 36 values only.</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="16.13"/>
                    <measurement group_id="O2" value="2.5" spread="12.40"/>
                    <measurement group_id="O3" value="-3.3" spread="11.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Reduced TAC, Month 36</title>
          <description>Reduced TAC, Month 36</description>
        </group>
        <group group_id="E2">
          <title>TAC Elimination, Month 36</title>
          <description>TAC Elimination, Month 36</description>
        </group>
        <group group_id="E3">
          <title>TAC Control, Month 36</title>
          <description>TAC Control, Month 36</description>
        </group>
        <group group_id="E4">
          <title>Reduced RAD + TAC, Month 48</title>
          <description>Reduced RAD + TAC, Month 48</description>
        </group>
        <group group_id="E5">
          <title>TAC Elimination, Month 48</title>
          <description>TAC Elimination, Month 48</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Haemolytic uraemic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Biliary ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hepatic artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hepatic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Epstein-Barr viraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Graft loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Incisional hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pulmonary granuloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

